ノーティラス・バイオテクノロジー
Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.12 | $0 | -$14M |
| 2025 Q4 | -0.11 | $0 | -$13M |
| 2025 Q3 | -0.11 | $0 | -$11M |
| 2025 Q2 | -0.12 | $0 | -$14M |
| 2025 Q1 | -0.13 | $0 | -$14M |
| 2024 Q4 | -0.14 | $0 | -$15M |
| 2024 Q3 |
| -0.13 |
| $0 |
| -$14M |
| 2024 Q2 | -0.14 | $0 | -$16M |